Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. At the time of writing this protocol it was not known whether radiation therapy was more effective than temozolomide in treating gliomas. The purpose if this randomized phase III trial was to study radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research, CCTG, MRC-NCRI, Brain Tumour Group

Closing Date of Accrual

March 2010

Trial Chairperson

Dr Claire Phillips, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

Tour de Cure grants for TROG Cancer Research trials
9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital